The Hepatitis Fund Welcomes New Board President

Geneva, Switzerland: The Hepatitis Fund (aka “EndHep2030”), the only grantmaking foundation dedicated to the global campaign to eliminate viral hepatitis as a major public health threat, recently announced the election of Gregg Alton as its next president of the Board of Directors, succeeding Wangsheng Li, co-founder of the EndHep2030 initiative since 2016 and founding president of The Hepatitis Fund since its inception in 2019.

“We are very fortunate to have Gregg join our Board to lead the organization in our next stage of growth,” observed Wangsheng Li. “Gregg brings a broad perspective that is critical for an international health organization like The Hepatitis Fund. His personal commitment and extensive experience in public health, philanthropy, government affairs and policy, and publicprivate partnership is exactly what we need to thrive in a challenging environment as we face today,” continued Li.

A biopharmaceutical industry veteran, Gregg Alton was interim CEO and Chief Patient Officer at Gilead Sciences. In addition to his broad corporate experience, Mr. Alton has served on a number of health-related advisory boards, including the President’s Advisory Council on HIV/AIDS. He is also a board member for several non-profit organizations, including Black Women’s Health Imperative, AIDSVu, and the Boys and Girls Clubs of Oakland.

Accepting the Board’s appointment, Gregg expressed that “I’m deeply honored to be entrusted to lead The Hepatitis Fund, whose mission and mandate I feel strongly about. I look forward to working with the Board and the staff in guiding the organization into a highly effective foundation with great impact in the global health space.”

About The Hepatitis Fund
The Hepatitis Fund is a Geneva-based charitable foundation, evolving from the EndHep2030 project under the auspices of the Rockefeller Philanthropy Advisors (New York City). With seed funding from ZeShan Foundation (Hong Kong SAR, China), The Hepatitis Fund has been at the forefront in mobilizing philanthropic investment in supporting global efforts to eliminate viral hepatitis, a pandemic that has infected one in three people worldwide and causes around 1,400,000 deaths each year. Globally 325 million people are chronically infected with a hepatitis. Through catalytic funding initiatives, the EndHep2030 grants programme strategically focuses on the Asia and Pacific and Sub-Saharan African regions while not losing sight of the rest of the world. This geographic emphasis guides our grants programme by focusing on three strategic areas: accelerating planning and implementation of national strategies, integrating hepatitis services delivery with Universal Health Coverage, and strengthening public health response capability.

To learn more and contribute, please visit endhep2030.org.